Loading
Life sciences · Phase 2 Trial
ClinicalTrials.gov · November 5, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Phase 2 Trial.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT04619420). This is a study registration, not published results. Lead sponsor: Janssen Research & Development, LLC. Recruitment status: TERMINATED. Phase: PHASE2. Study type: INTERVENTIONAL. Enrollment: 523 participants (ACTUAL). Conditions: Alzheimer Disease, Cognitive Dysfunction, Dementia. Interventions: DRUG: JNJ-63733657; DRUG: Placebo. Primary outcome measures: Double-blind (DB) Treatment Period: Change From Baseline in Integrated Alzheimer's Disease Rating Scale for Mild Cognitive Impairment (iADRS-MCI) Total Score at Week 104 , Baseline (Day 1), Week 104. Brief summary: The primary purpose of this study is to evaluate the effect of JNJ-63733657 versus placebo on clinical decline as measured by the Integrated Alzheimer's Disease Rating Scale (iADRS), a composite of cognition and function.